View Older Stories View More Recent Stories

Dec 21, 2020 01:33PM Form 4 Surface Oncology, Inc. For: Dec 17 Filed by: Atlas Venture Associates IX, L.P.
Dec 17, 2020 06:20PM Form 4 Generation Bio Co. For: Dec 15 Filed by: Atlas Venture Opportunity Fund I, L.P.
Dec 17, 2020 04:15PM Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%
Dec 17, 2020 01:15AM Cadent Therapeutics Enters Agreement to be Acquired by Novartis
Dec 8, 2020 08:00AM Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases
Dec 8, 2020 06:00AM Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing
Nov 30, 2020 07:00AM Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a N
Nov 19, 2020 11:00AM Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study
Nov 19, 2020 09:36AM The Alliance for Regenerative Medicine Announces Record Sector Financing in 2020
Nov 19, 2020 09:17AM The Alliance for Regenerative Medicine Announces Record Sector Financing in 2020
Nov 19, 2020 09:17AM The Alliance for Regenerative Medicine Announces Record Sector Financing in 2020
Nov 19, 2020 07:00AM Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board
Nov 16, 2020 07:00AM Atlas Venture Welcomes Rajesh Devraj, PhD, as Venture Partner
Nov 12, 2020 07:13AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 12, 2020 07:13AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 12, 2020 07:13AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 12, 2020 07:13AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 12, 2020 07:13AM Form 13F-NT ATLAS VENTURE FUND VI For: Sep 30
Nov 10, 2020 07:00AM Korro Bio Appoints Ram Aiyar, Ph.D., MBA, as Chief Executive Officer
Nov 9, 2020 08:02AM Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting
Oct 29, 2020 07:00AM Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
Oct 29, 2020 02:15AM Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
Oct 28, 2020 05:20AM Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys
Oct 26, 2020 06:00AM Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0
Oct 22, 2020 07:00AM Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines
Oct 15, 2020 09:22AM Lilly (LLY) to Acquire Disarm Therapeutics for $135 Million Upfront
Oct 15, 2020 09:20AM Lilly Announces Agreement to Acquire Disarm Therapeutics
Oct 15, 2020 07:30AM Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration
Oct 1, 2020 07:00AM Korro Bio Appoints Omar Khwaja, M.D., Ph.D. to its Board of Directors
Sep 28, 2020 07:00AM Quench Bio is named one of Fierce Biotech's "Fierce 15" Biotech Companies of 2020
Sep 23, 2020 06:57PM Form 4 Dyne Therapeutics, Inc. For: Sep 21 Filed by: Atlas Venture Associates Opportunity I, L.P.
Sep 21, 2020 08:32AM KromaTiD Announces the Appointment of Vic Myer, PhD to its Board of Directors
Sep 17, 2020 04:51PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Sep 17, 2020 04:49PM Form 4 Replimune Group, Inc. For: Sep 15 Filed by: Atlas Venture Fund X, L.P.
Sep 16, 2020 08:40PM Form 3 Dyne Therapeutics, Inc. For: Sep 16 Filed by: Atlas Venture Fund XI, L.P.
Sep 15, 2020 01:10PM Compass Therapeutics, Inc. Provides Corporate Update
Sep 15, 2020 01:10PM Compass Therapeutics, Inc. Provides Corporate Update
Sep 10, 2020 07:00AM Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics
Aug 25, 2020 04:31PM Form 4 Kymera Therapeutics, For: Aug 25 Filed by: Atlas Venture Associates Opportunity I, LLC
Aug 20, 2020 08:40PM Form 3 Kymera Therapeutics, For: Aug 20 Filed by: Atlas Venture Fund X, L.P.
Aug 18, 2020 07:00AM Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical Officer
Aug 12, 2020 07:00AM Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade
Aug 11, 2020 05:00PM Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
Aug 10, 2020 07:00AM Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases
Aug 6, 2020 02:09PM Form 13F-NT ATLAS VENTURE FUND VI For: Jun 30
Aug 6, 2020 02:06PM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 6, 2020 02:03PM Form 13F-NT Atlas Venture Associates For: Jun 30
Aug 6, 2020 02:01PM Form 13F-HR Atlas Venture Associates For: Jun 30
Aug 6, 2020 01:59PM Form 13F-HR Atlas Venture Advisors, For: Jun 30
Aug 6, 2020 09:40AM Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Potential Disease-Modifying Pulmonary Arterial Hypertension Therapy
View More Recent Stories View Older Stories